Objectives: To compare the treatment outcome of tamsulosin 0.4 mg (TAM) with or without solifenacin 5 mg (SOL) for the most bothersome symptom in male lower urinary tract symptoms (LUTS) with overactive bladder (OAB). Subjects and Methods: Male LUTS/OAB (≥50 years) patients who had a total International Prostate Symptom Score (I-PSS) of ≥12, I-PSS urgency-related question of ≥2, and quality of life (QoL) of ≥3 points were enrolled. Patients who complained of storage symptoms as the most bothersome were included in the ‘storage' group. Patients who complained of voiding symptoms as the most bothersome were included in the ‘voiding' group. The change in the I-PSS was compared between the two groups 4 weeks after commencing treatment. Results: In the storage group, 172 were able to finish this study (TAM: 88, TAM + SOL: 84). The improvement of I-PSS and QoL with TAM + SOL was significantly greater than with TAM alone (p < 0.001). In the voiding group, 108 were able to finish the study (TAM: 54, TAM + SOL: 54). The improvement of I-PSS and QoL with TAM alone was significantly greater than with TAM + SOL (p < 0.001). Conclusions: The most bothersome symptom in male LUTS/OAB should be considered when choosing the appropriate medical treatment.

Keywords:
Prostatic hyperplasia, Prostatism, Outcome assessment
1.
Chapple CR: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004;94:738-744.
2.
Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-658.
3.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56:534-541.
4.
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W: Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009;182:2825-2830.
5.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-2328.
6.
Jepsen JV, Bruskewitz RC: Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 1998;51:13-18.
7.
Welch G, Weinger K, Barry MJ: Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002;59:245-250.
8.
Lee YS, Lee HN, Han JY, Choo MS, Lee KS: Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study. J Urol 2011;185:1003-1009.
9.
Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Kelleher CJ, Trocio J: Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J 2011;22:937-946.
10.
Brubaker L, Piault EC, Tully SE, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Khullar V, Kelleher CJ, Trocio J: Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms. Int J Clin Pract 2013;67:342-350.
11.
Chang HS, Park CH, Kim DK, Park JK, Hong SJ, Chung BH, Lee JG, Kim CS, Lee KS, Kim JC: Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. Urology 2010;75:1156-1161.
12.
Viktrup L, Hayes RP, Wang P, Shen W: Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urol 2012;12:30.
13.
Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, Yokoyama O, Seki N, Yoshida M: Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology 2011;78:126-133.
14.
Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY: Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol 2014;46:523-529.
15.
Apostolidis A, Kirana PS, Chiu G, Link C, Tsiouprou M, Hatzichristou D: Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study. Eur Urol 2009;56:937-947.
16.
Roe B, Doll H, Wilson K: Help seeking behaviour and health and social services utilisation by people suffering from urinary incontinence. Int J Nurs Stud 1999;36:245-253.
17.
Teunissen D, van Weel C, Lagro-Janssen T: Urinary incontinence in older people living in the community: examining help-seeking behaviour. Br J Gen Pract 2005;55:776-782.
18.
Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R: Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006;60:745-751.
19.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
20.
Lee SW, Doo SW, Yang WJ, Song YS: Importance of relieving the most bothersome symptom for improving quality of life in male patients with lower urinary tract symptoms. Urology 2012;80:684-687.
21.
Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z: Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72:1061-1067; discussion 1067.
22.
Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ: The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue - the BSW. Value Health 2005;8(suppl 1):S25-S34.
23.
Shah S, Nitti VW: Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol 2009;11:196-202.
24.
Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D: Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000.
25.
Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, Masumori N: Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. Urology 2013;82:887-893.
26.
Krhut J, Gartner M, Petzel M, Sykora R, Nemec D, Tvrdik J, Skoupa J: Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients. Scand J Urol 2014;48:79-83.
27.
Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D: Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013;35:1744-1751.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.